Skip to main content
OpenTrials
Completed

NCT Number: NCT01096212

Efficacy and Safety of Sevofran in Patients Scheduled for Elective Surgery Under General Anesthesia

Sevoflurane is currently being used in more than 100 countries worldwide with an estimated 100 million operations having been performed using sevoflurane as a general anesthetic. After the expiry of the patent on sevoflurane as a pharmaceutical drug, a generic product (Sevofran®; Hana pharmacy, Co. Ltd, Seoul, Korea) has been launched. The aims of this study were to investigate the efficacy (mean minimum alveolar concentration), recovery characteristics (time to recovery of consciousness (ROC) and recovery, and BIS values at ROC and orientation), and safety (incidence and severity of adverse events) of generic sevoflurane in patients undergoing elective surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Asan Medical Center, Seoul, South Korea

Loading trial locations.

About this study

Patients were randomly allocated to experimental group (generic sevoflurane) and active comparator group (original sevoflurane). Once in the operating room, patients were monitored with electrocardiography, non invasive blood pressure, pulse oximetry (Datex-Ohmeda S/5, Planar Systems, Inc., Beaverton, OR, USA) and BIS (Aspect 2000, Aspect Medical Systems, Inc., Newton, MA, USA).

Anesthesia was induced with fentanyl (2 μg/kg) and propofol (2mg/kg). When patients were unconscious, original or generic sevoflurane was administered. Tracheal intubation was facilitated by administering rocuronium 0.6 mg/kg. The lungs of the patients were then ventilated with oxygen in air (1:2), and the ventilation rate was adjusted to maintain the end-tidal carbon dioxide partial pressure between 35 and 45 mmHg. The concentrations of carbon dioxide, sevoflurane, and oxygen were measured continuously using an infrared anesthetic gas analyzer (Datex-Ohmeda S/5, Planar Systems, Inc., Beaverton, OR, USA), which was calibrated before anesthesia for each patient using a standard gas mixture.

The inspired concentration of sevoflurane was adjusted to maintain BIS values < 60 and stable haemodynamics (systolic arterial pressure (SAP) > 80 mmHg and heart rate (HR) > 45 beats/min). Also, it was titrated to prevent signs of inadequate anesthesia (sweating, facial flushing, movement and swallowing, HR > 90 beats/min without evidence of hypovolemia, and a 15 mmHg increase in SAP, compared with baseline SAP). Fentanyl 1 μg/kg was given if needed to resolve of signs of inadequate anesthesia.

Concentration of compound A, formaldehyde, and methadone were measured at preset interval: 30, 60, 90, 120, 150, 180 min after administration of sevoflurane. Blood and urine samples were taken at preset interval for analyzing concentration of inorganic fluoride: 1 hr after administration of sevoflurane and every 2 hr during maintenance of anesthesia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients scheduled for elective surgery under general anesthesia
  • American Society Anesthesiologists Physical Status (ASA PS) 1 or 2
  • Aged 19 years or above

Exclusion criteria

  • ASA PS 3 or above
  • aged under 19 years
  • Contraindications against the use of sevoflurane
  • Abnormal laboratory finding with clinical significance
  • Evidence of pregnancy
  • History of alcohol or drug abuse
  • Hemoglobin < 11 mg/dl
  • Neurological or psychiatric disease
  • Unable or unwilling to give informed consent

Treatment and study plan

original sevoflurane

Drug

Sevoflurane content: 99.9985%, compound A: 4.6 ppm, water content (sample was opened, sealed and stored for 2 weeks): 0.072% w/v

Other names: Sevorane® (Abott Korea Ltd, Seoul, Korea)

generic sevoflurane

Drug

Sevoflurane content: 99.99%, compound A: 3.8 ppm, water content (sample was opened, sealed and stored for 2 weeks) : 0.044% w/v

Other names: Sevofran® (Hana Pharmacy, Co. Ltd, Seoul, Korea)

Primary outcomes

  1. Comparison of mean minimum alveolar concentration between original and generic sevoflurane

    Time frame: During mainenance of anesthesia under general anesthesia

    Minimum alveolar concentration was determined by end-tidal sevoflurane concentrations. Mean MAC was calculated as following equation,

    Mean MAC = (MAC * hour) / (maintenance time from administration of hypnotic agent (propofol) for acquring loss of consciousness to extubation)

Secondary outcomes

  1. Comparison of secondary efficacy and safety endpoints between two inhalation agents

    Time frame: During maintenance of anesthesia under general anesthesia

    Secondary efficacy and safety characteristics include following items.

    • Anesthesia exposure: MAC * hour [Time frame: maintenanane period of anesthesia]
    • Bispectral index, BIS [Time frame: time to recovery of consciousnessn, time to recovery of orientation]
    • Adverse event [Time frame: maintenanane period of anesthesia]
    • Incidence and severity of postopertive nausea and vomiting [Time frame: 24 hours postoperatively]
    • Concentrations of compound A, formaldehyde, methanol [Time frame: 30, 60, 90, 120, 150, 180 min after sevoflurane administration]

Sponsors and collaborators

Lead sponsor

Asan Medical Center

Other

Collaborators

  • National Clinical Research Coordination Center, Seoul, Korea

Registry information

Official study title

A Multi-center, Open-Label, Randomized, Active-controlled, Parallel, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Sevofran in Patients Scheduled for Elective Surgery Under General Anesthesia

Important dates

Study start
2008
Primary completion
2009
Study completion
2010
First posted
Mar 31, 2010
Registry last updated
Mar 31, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.